This study was undertaken to assess the efficacy of a stan dard regime of high-dose systemic oral corticosteroids in the management of retinal vasculitis. The study was per formed because the single most common reason for refer ral to our specialist clinic is the apparent failure of patients to respond to a course of systemic steroids, which in most cases appeared to be due to an inadequate initial dose. A retrospective study of 29 patients (30 treatment episodes) with sight-threatening retinal vasculitis man aged initially with high-dose systemic steroids was eval uated 1 year after treatment. Patients included in the study all started treatment with � 1 mg/kg prednisolone and remained on a high steroid dose (�40 mg predniso lone) for at least 5 weeks. No patient was on any other immunosuppressive agent at the start of the study. Thera peutic success for this regime, as judged by improvement in visual acuity, was 60%, improving to 77% with addi tion of other immunosuppressive agents. Eight patients required additional immunosuppressives. Although documented side-effects of steroids were common (50% of cases managed on steroids alone), in only 5 patients were they therapeutically important. Tw elve of the 22 patients managed on high-dose steroids alone were off treatment at 12 months. There was no correlation at any stage between visual acuity, activity index or relapses and the final visual outcome at 12 months. Seven cases had a poor visual outcome and the causes for this included relapse in the twelfth month of follow-up, persistent cys toid macular oedema and lens opacity. These results sug gest that high-dose oral steroids should be tried in the initial management of such patients before contemplating other more complicated regimes or accepting a poor visual outcome.
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Corticosteroids were first introduced for the management of sight -threatening retinal vasculitis in the 1950s.1. 2 An improved understanding of the pathological mechanisms underlying this blinding disease' has led to the utilisation of other immunosuppressive agents,4 but systemic steroids remain the mainstay of treatment. A wealth of information exists in the literature on these other, newer immuno suppressives, but there is a surprising paucity of data eval uating steroid regimes. Corticosteroid treatment regimes tend to be empirical, and advocate starting with a high dose of steroids (1-2 mg/kg) and reducing the dose according to the patient's response. [5] [6] [7] The most common reason for patients to be referred to our specialist retinal vasculitis clinic is failure of response to a course of systemic steroids. On each occasion this appeared to be an inadequate course of steroids beginning with 40 mg prednisolone daily or less. Our practice is to employ a high-dose steroid regime (80 mg prednisolone for 4 days, 60 mg prednisolone for 4 days, 40 mg pred nisolone for I month, reducing thereafter) in all such patients. This retrospective study was carried out to eval uate the therapeutic efficacy of our regime; if a simple oral regime is effective, then there is no need to resort to intra venous treatment or newer immunosuppressives with all the attendant sophisticated medical back-up often not practical in eye units.
PATIENTS AND METHODS
All case notes of patients attending the Medical Eye Unit, St Thomas' Hospital, with retinal vasculitis in the past 10 years were examined. Patients included in the study received a course of high-dose systemic steroids for active retinal vasculitis, were on no other immunosuppressive agents at the start of the study period, and had complete follow-up records for I year. Patients were excluded if they had undergone any form of ocular surgery or laser therapy during the follow-up period, and if they were started on any immunosuppressive agents other than azathioprine or cyclosporin A after the high-dose steroids (this was to exclude patients who had received immuno suppressives now not routinely employed at St Thomas'). A treatment episode was defined as a course of high-dose systemic steroids administered for active retinal vasculitis with complete follow-up for I year. A course of high-dose steroids was defined as 80 mg prednisolone for 4 days, 60 mg prednisolone for 4 days, 40 mg prednisolone for I month, reducing thereafter. Indications for treatment were a marked increase in activity of retinal vasculitis alone or increased activity associated with a drop in visual acuity. Case notes were assessed at minus 1 month, zero, I month, 3 months, 6 months and 12 months, and details of treatment, disease activity, Snellen visual acuity, side- effects of the drugs and results of fluorescein angiography recorded. Disease activity was assessed using a weighted visual morbidity scale. 8 Outcome was assessed in terms of changes in visual acuity by the end of the study period. Visual acuity was graded as follows: grade I, 6/6 or better; grade II, 6/9 or 6/12; grade Ill, 6/18 to 6/36; and grade IV, 6/60 or worse. A successful visual outcome was defined as either (I) maintenance of visual acuity of 6/12 or better, or (2) improvement of one or more grades by the end of the study period. Patients who did not fulfil either of these cri teria were considered to have a poor visual outcome. A relapse was defined as an increase in visual symptoms (blurred vision, floaters) associated with an increase in vit reous cellularity,9 and did not necessarily involve a drop in visual acuity.
RESULTS

Patients' Characteristics
Two hundred and fifty case notes were examined of patients who had had systemic immunosuppressives for retinal vasculitis. Twenty-nine patients were found to fit the inclusion criteria and had undergone 30 treatment epi sodes. Eight patients had associated pathology: 3 sarcoi dosis, 3 birdshot chorioretinopathy, and 2 Beh<;:eCs disease. The remaining 21 patients had isolated retinal vasculitis. One of the patients with isolated disease quali fied for two treatment episodes. Five of the 30 cases had treatment for unilateral disease, although in only 1 of these (with idiopathic retinal vasculitis) the other eye had never been involved. At minus 1 month, 8 patients were on no treatment, 3 were on topical steroid and the remaining 19 were on systemic steroid with doses ranging from 2.5 mg to 30 mg prednisolone. Although the activity index at zero time, i.e. at initiation of high-dose steroids, was variable (6-34, with a mean of 12), patients fell into two groups: those with marked disease activity associated with a high activity score (21/30) and those with persistent grumbling activity unresponsive to low-dose systemic steroids Fig. 1 . None of the cases had their initial visual acuity reduced secondary to macular ischaemia. Twenty-two of the 30 treatment episodes (73%) were managed with steroids alone throughout the year. This group consisted of 17 cases of isolated vasculitis, 3 of birdshot chorioretinopathy and 2 of sarcoidosis. The remaining 8 treatment episodes required additional immunosuppressive therapy (Table I) : 6 (20%) with azathioprine (3 isolated vasculitis, 2 Behc;et's disease, 1 sarcoidosis) and 2 (6%) with cyclosporin A (2 isolated vasculitis). The time at which these drugs was added was variable, but tended to be in the first 4 months.
Twelve of the 22 treatment episodes managed on steroids alone were off treatment by 12 months. Six of the remaining 10 patients still on prednisolone at 12 months were on 10 mg prednisolone per day or less; the highest maintenance dose of the remaining patients was 20 mg/day.
Side-effects of steroids were common (Table II) . Twelve of the 22 (54%) treatment episodes managed on steroids alone resulted in documented side-effects. Two of these cases required therapeutic intervention: 1 patient developed diabetes mellitus requiring oral hypoglycaem ics, while the other became hypertensive requiring hypo tensives. In 3 further cases hyperglycaemia or marked weight increase required additional immunosuppressive therapy (azathioprine in all 3 cases) to enable the pred nisolone dose to be reduced.
Disease Course and Outcome
Nine cases in all suffered a relapse during the 12 month period (Table III) . Two cases had two relapses. Seven of the total II relapses occurred between 5 and 7 months. Twenty-three (77%) of the 30 treatment episodes resulted in a successful visual outcome at 12 months (see Fig. 1 ). Eighteen (60%) patients with a successful visual outcome were managed on steroids alone, and of these 10 were off treatment at 12 months; 4 (13%) were managed on steroids and azathioprine, and of these, 1 was off treat ment at 12 months. One was managed on prednisolone and cyclosporin A, and remained on this treatment at 12 months. There was no correlation at any stage between either visual acuity or activity index and good visual out come at 12 months. Furthermore, there did not appear to be any relationship between relapses and final visual outcome.
Seven (23%) patients had a poor visual outcome, for a variety of reasons (Table IV) . It should be noted that patient MA who had a poor visual outcome at 12 months due to increasing lens opacity. had good visual function restored after cataract surgery performed outside the study period. Two of the 9 patients who at inclusion in the study had persistent grumbling disease activity despite low-dose systemic steroids, had a poor visual outcome (patients PS and SP). 
DISCUSSION
This paper presents 29 patients with retinal vasculitis managed with a course of high-dose steroids and followed up for I year. The study was carried out to assess our current treatment regime and to evaluate a number of fac tors including efficacy, side-effects and optimum length of treatment. Only 2 patients had Behc;et's disease, which is known to have a poor visual prognosis, but a successful visual outcome was achieved at the 12 month follow-up in a total of 77% cases, a third of whom were off all treat ment. Those receiving steroids only achieved a 60% visual success. The fact that 7 patients who had previously failed to respond to a lower dose of systemic steroids and now had a favourable outcome supports our clinical impression that the initial dose of steroids must be high (-I mg/kg) for at least I week and that patients must then take at least 0.5 mg/kg for a further month to optimise the chance of success. Surprisingly, there is little published in the literature on the efficacy of high-dose steroid regimes for comparison with our success rates, but Nussenblatt et al.7 carried out a double-masked study on 56 patients with idiopathic intermediate and posterior uveitis randomising them to high-dose oral prednisolone (80-60 mg starting dose, depending on body weight) versus cyclosporin A. It is not clear for how long the prednisolone was maintained above or equal to 40 mg prednisolone as in our study, but at the 3 month follow-up 13 of 28 (46%) cases were deemed a success (improvement in visual acuity by 3 lines or more in at least one eye, or improvement of at least two incre ments on their vitreous haze scoring).
Our study was retrospective and thereby limited in a number of respects. It would be of interest to carry out a prospective study randomising suitable patients with ret inal vasculitis to compare directly this high-dose steroid regime (with maintenance of 40 mg prednisolone for at Right optic neuropathy
Poor treatment compliance least 5 weeks) with a regime in which steroid dose is titrated to patient response. Studying the 9 of 30 cases with grumbling disease unresponsive to low-dose steroids does support the proposition that a course of high-dose steroids can be effective in controlling disease. Although the numbers are small and it is therefore difficult to draw firm conclusions, 7 of these 9 cases (77%) had a successful visual outcome -interestingly in exact proportion to the success rate overall. All the systemic drugs currently in clinical use for treat ment of posterior uveitis have serious side-effects.4,13 Side-effects of steroids are common and well docu mented,IO and just over half of our patients managed on steroids alone experienced them. Only 2 required thera peutic intervention for hyperglycaemia and hypertension, while a further 3 required addition of azathioprine to allow reduction in the steroid dose (total 5/30 = 16%). Half the patients managed on steroid alone were off treatment at 12 months, while three-quarters of those still on pred nisolone were on a maintenance dose of 10 mg or less. The use of immunosuppressive agents for life-threatening conditions is well established,11.1 2 but their use in the management of disorders such as uveitis must necessarily be more circumspect. Currently cyclosporin A and azath ioprine are the immunosuppressive agents most com monly used in the management of uveitis. Bone marrow suppression and gastrointestinal upset are the side-effects of azathioprine that most commonly limit its clinical role.13.14 This was illustrated in our study, as 1 of the 2 patients who had their azathioprine discontinued did so due to gastrointestinal upset (patient RS), while in the second it was stopped due to abnormal liver function tests (patient NW). A third patient on azathioprine (PH) devel oped a transient lymphopenia which did not warrant dis continuing the drug. The major side-effects of cyclosporin that limit its use are nephrotoxicity and hypertension. These have been widely reported in both transplant patients 15 and uveitis patients. [16] [17] [18] The changes in renal function appear to be largely reversible, 1 2 but more worry ing are the seemingly non-reversible histological changes on renal biopsy in both transplant patients 19 and uveitis patients. 2 0. 2 1
In conclusion, our study showed a 60% success rate in visual outcome at I year in posterior uveitis patients man aged on steroids alone, improving to 77% with the addi tion of other immunosuppressive agents. We feel this good result may well be due to the unique feature of this regime in that patients are kept on a high initial dose of systemic steroid for at least 5 weeks. This study illustrates that oral steroids still have a key role to play in the management of posterior uveitis, especially as both our understanding and experience with them is much greater than with the newer immunosuppressive agents.
This study will provide a useful standard with which to compare the results of more sophisticated regimes of intravenous therapy or modem immunomodulators.
